Marshall Wace North America’s Charles River Laboratories CRL Stock Holding History

Marshall Wace North America’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$84.5M	Buy	204,845 +24,726	+14%	+$10.3M	0.36%	55
2021 Q2	$66.6M	Sell	180,119 -13,470	-7%	-$4.5M	0.28%	74
2021 Q1	$56.1M	Buy	+193,589	New	+$53.8M	0.23%	98
2020 Q3	–	Sell	-14,903	Closed	-$2.6M	–	1252
2020 Q2	$2.6M	Buy	+14,903	New	+$2.38M	0.02%	513
2019 Q4	–	Sell	-27,777	Closed	-$3.68M	–	1331
2019 Q3	$3.68M	Buy	+27,777	New	+$3.72M	0.02%	423
2019 Q2	–	Sell	-508	Closed	-$74K	–	1233
2019 Q1	$74K	Sell	508 -1,022	-67%	-$134K	﹤0.01%	1175
2018 Q4	$173K	Buy	+1,530	New	+$192K	﹤0.01%	981
2018 Q3	–	Sell	-57,307	Closed	-$6.43M	–	992
2018 Q2	$6.43M	Buy	+57,307	New	+$6.2M	0.04%	454
2017 Q4	–	Sell	-58,103	Closed	-$6.28M	–	1403
2017 Q3	$6.28M	Sell	58,103 -50,672	-47%	-$5.21M	0.04%	483
2017 Q2	$11M	Sell	108,775 -328,504	-75%	-$30.2M	0.08%	298
2017 Q1	$39.4M	Buy	+437,279	New	+$37.1M	0.31%	90

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Marshall Wace North America's CRL Position: Q3 2021 in Review

Marshall Wace North America increased its Charles River Laboratories (CRL) stake by 14% in Q3 2021, buying an estimated $10.3M and bringing the position to 204,845 shares worth $84.5M. The position accounts for 0.36% of the portfolio, ranked #55.

Marshall Wace North America first reported a position in CRL in Q1 2017 and has held it in 11 quarters since. 677 funds tracked by Wall St. Rank hold CRL as of Q3 2021.

Marshall Wace North America held 204,845 shares of Charles River Laboratories worth $84.5M as of Q3 2021.
Marshall Wace North America bought 24,726 Charles River Laboratories shares in Q3 2021, an estimated $10.3M.
Charles River Laboratories made up 0.36% of Marshall Wace North America's portfolio in Q3 2021, its #55 holding.
Marshall Wace North America first reported a position in Charles River Laboratories in Q1 2017 and has held it in 11 quarters since.
677 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.